Key Highlights

  • MMED shares traded up 11.06% intraday to $22.50, touching a fresh 52-week high from a $20.26 prior close.
  • Fiscal Q1 2027 net sales rose 15.8% organically to $843 million, topping internal expectations.
  • Insulin pump sales grew 21.5% and continuous glucose monitor sales grew 19.9%.
  • Management raised full-year organic Revenue growth guidance to approximately 10.5% and reaffirmed a Buy rating with a raised $28 price target from one research firm.

Diabetes Device Maker Tops Expectations and Raises Guidance

MiniMed Group (NASDAQ:MMED) shares surged to a fresh 52-week high after the insulin delivery company reported fiscal Q1 2027 results that topped internal expectations, with net sales of $843 million, up 15.8% organically, driven by strong growth in pumps and continuous glucose monitors. The company also narrowed losses to $5 million versus a $13 million loss a year ago.

MiniMed Group is a global medical technology company that develops, manufactures, and markets an integrated portfolio of diabetes management solutions, including automated insulin delivery systems, insulin pumps, continuous glucose monitors, and its CareLink software platform. The company was recently spun off from Medtronic (NYSE:MDT) in March 2026.

Management Raises Full-Year Growth and Margin Guidance

Management raised its full-year organic revenue growth outlook to approximately 10.5%, up from roughly 10%, while reiterating an adjusted EBITDA margin guidance of approximately 16% for the year. One research firm responded by lifting its price target to $28 from $25 while reiterating a Buy rating, citing pipeline progress. MiniMed Group carries a market Capitalization of roughly $6.32 billion.

Heavy Institutional Accumulation Supports the Rally

The stock's rally also follows recent heavy institutional accumulation, including a 7,527% increase in one large asset manager's stake last quarter, even as broader healthcare peers and the market face pressure from rising oil prices and Treasury yields tied to Middle East tensions. The company serves people with Type 1 and Type 2 diabetes across more than 80 countries through direct-to-consumer channels and healthcare providers.

Pipeline Progress Adds to the Long-term Growth Story

Key product launches drove momentum during the quarter, with a new pump launch boosting sales by more than 20% year over year and new prescriber growth of 24%. A fully closed-loop algorithm completed pivotal trial enrollment ahead of schedule, with launch expected in the second half of calendar 2027, adding a longer-term catalyst beyond today's Earnings beat.

Pivotal Trial Progress Will Be the Next Milestone

MiniMed Group's near-term trajectory will likely continue to benefit from the momentum in its core pump and continuous glucose monitor businesses. Investors will also watch for further updates on the company's closed-loop algorithm pivotal trial as it approaches its planned 2027 launch.